Radiopharm (ASX: RAD; NASDAQ: RADX) Advances Clinical Strategy with New Lutetium-177 Supply Deal

May 19, 2025 12:28 PM AEST | By Aditi Sarkar

Google News:

Radiopharm (ASX: RAD; NASDAQ: RADX) Advances Clinical Strategy with New Lutetium-177 Supply Deal — Image source: Company update

Recent News

China Steel Slump Hits Iron Ore Demand, Pressure Mounts on ASX 200 Min...

Copper Smelting Inactivity Peaks Again Amid Global Shifts; Eyes on ASX...

RCF Finalises RME Acquisition in Move to Strengthen asx 200 Mining Ser...

Moho Resources (ASX:MOH) Identifies Gold Anomaly at Silver Swan North,...

Highlights

Radiopharm has signed a supply a with ITM for high-purity non-carrier-added Lutetium-177 (n.c.a.¹⁷⁷Lu).

The agreement has secured a critical radioisotope supply for Radiopharm’s clinical and preclinical cancer programs.

ITM’s n.c.a.¹⁷⁷Lu is FDA-registered and EU-approved under the brand EndolucinBeta®.

Radiopharm’s CEO, Riccardo Canevari, described the agreement as a major step toward ensuring clinical reliability and accelerating development timelines.

RAD shares up 5% after the update.

Radiopharm Theranostics Ltd (ASX: RAD; NASDAQ: RADX), a clinical-stage radiotherapeutics company, has announced a significant milestone through a newly signed supply agreement with ITM Isotope Technologies Munich SE (ITM), a global leader in radiopharmaceutical biotechnology. Under this deal, Radiopharm will gain access to ITM’s medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu), a critical isotope used in targeted cancer therapies.

“Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs. Lutetium-177 is required for three of our more advanced assets and this supply agreement with a radiopharmaceutical leader like ITM is another important step to ensure quality, reliability, and redundancy in our clinical development plans,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.

Radiopharm’s stock traded at AUD 0.023, up 4.55%, at the time of writing on 19 May 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.